Literature DB >> 31938418

SK-Hep1: not hepatocellular carcinoma cells but a cell model for liver sinusoidal endothelial cells.

Yang Tai1, Jin-Hang Gao1,2,3, Chong Zhao2,3, Huan Tong1, Shu-Ping Zheng4, Zhi-Yin Huang1, Rui Liu2,3, Cheng-Wei Tang1,2,3, Jing Li1.   

Abstract

SK-Hep1 cells serve as a cell model of hepatocellular carcinoma and hepatocyte biology. However, SK-Hep1 cells are markedly different from normal hepatocytes and other hepatocellular carcinoma cells in their gene expression and protein levels. Furthermore, endothelial-specific makers and morphological characteristics are found in SK-Hep1 cells, indicating an endothelial origin. To confirm their cell phenotype, we investigated and compared the surface ultrastructure, endothelial function, and molecular markers of SK-Hep1 cells in vitro and in vivo. The results revealed that SK-Hep1 cells expressed endothelial-specific makers and exhibited the endothelial function of endocytosis and tubular formation. Capillary-like structures with CD31 expression were also observed in SK-Hep1 allografts in nude mice. Moreover, SK-Hep1 cells possessed fenestrae without diaphragms, consistent with liver sinusoidal endothelial cells, as seen by electron microscopy. In conclusion, SK-Hep1 cells would be better considered a cell model for liver sinusoidal endothelial cells instead of hepatocellular carcinoma cells. IJCEP
Copyright © 2018.

Entities:  

Keywords:  Hepatocellular carcinoma; endocytosis; fenestration; liver sinusoidal endothelial cell; tubular formation

Year:  2018        PMID: 31938418      PMCID: PMC6958242     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  8 in total

1.  BRD4 inhibition induces synthetic lethality in ARID2-deficient hepatocellular carcinoma by increasing DNA damage.

Authors:  Dan-Dan He; Xue-Ying Shang; Na Wang; Guang-Xing Wang; Kun-Yan He; Lan Wang; Ze-Guang Han
Journal:  Oncogene       Date:  2022-01-11       Impact factor: 8.756

2.  Comparison of the [18F]-FDG and [18F]-FLT PET Tracers in the Evaluation of the Preclinical Proton Therapy Response in Hepatocellular Carcinoma.

Authors:  David Brasse; Hélène Burckel; Patrice Marchand; Marc Rousseau; Ali Ouadi; Marie Vanstalle; Christian Finck; Patrice Laquerriere; Frédéric Boisson
Journal:  Mol Imaging Biol       Date:  2021-04-13       Impact factor: 3.488

3.  PU.1 drives specification of pluripotent stem cell-derived endothelial cells to LSEC-like cells.

Authors:  Leo A van Grunsven; Catherine M Verfaillie; Jonathan De Smedt; Elise Anne van Os; Irene Talon; Sreya Ghosh; Burak Toprakhisar; Rodrigo Furtado Madeiro Da Costa; Samantha Zaunz; Marta Aguirre Vazquez; Ruben Boon; Pieter Baatsen; Ayla Smout; Stefaan Verhulst
Journal:  Cell Death Dis       Date:  2021-01-14       Impact factor: 8.469

4.  Extracellular and intracellular intermittent magnetic-fluid hyperthermia treatment of SK-Hep1 hepatocellular carcinoma cells based on magnetic nanoparticles coated with polystyrene sulfonic acid.

Authors:  Bo-Wei Chen; Guo-Wei Chiu; Yun-Chi He; Chih-Yu Huang; Hao-Ting Huang; Shian-Ying Sung; Chia-Ling Hsieh; Wei-Chieh Chang; Ming-Shinn Hsu; Zung-Hang Wei; Da-Jeng Yao
Journal:  PLoS One       Date:  2021-02-05       Impact factor: 3.240

5.  Expression and Functionality of Connexin-Based Channels in Human Liver Cancer Cell Lines.

Authors:  Kaat Leroy; Cícero Júlio Silva Costa; Alanah Pieters; Bruna Dos Santos Rodrigues; Raf Van Campenhout; Axelle Cooreman; Andrés Tabernilla; Bruno Cogliati; Mathieu Vinken
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

Review 6.  The Curious Case of the HepG2 Cell Line: 40 Years of Expertise.

Authors:  Viktoriia A Arzumanian; Olga I Kiseleva; Ekaterina V Poverennaya
Journal:  Int J Mol Sci       Date:  2021-12-04       Impact factor: 5.923

7.  Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM+ and CD90+ Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.

Authors:  Mohamed Moustafa; Katarzyna-Krystyna Dähling; Armin Günther; Leonie Riebandt; Daniel J Smit; Kristoffer Riecken; Carina Schröder; Ruimeng Zhuang; Till Krech; Malte Kriegs; Boris Fehse; Jakob R Izbicki; Lutz Fischer; Björn Nashan; Jun Li; Manfred Jücker
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

8.  Celecoxib reduces hepatic vascular resistance in portal hypertension by amelioration of endothelial oxidative stress.

Authors:  Yang Tai; Chong Zhao; Linhao Zhang; Shihang Tang; Xintong Jia; Huan Tong; Rui Liu; Chengwei Tang; Jinhang Gao
Journal:  J Cell Mol Med       Date:  2021-10-05       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.